# A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

Source: https://onco.cc/trials/nct04503265/  
OnCo record `nct04503265` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AMXI-5001:Dose Escalation Phase I in ovarian cancer, prostate cancer and pancreatic ductal adenocarcinoma, run by AtlasMedx, Incorporated, now recruiting.

## Summary

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies is a phase 1/2 interventional study registered as NCT04503265 by AtlasMedx, Incorporated, with 122 participants planned, started 2020-08-12 and due to reach its primary completion in 2026-08. Interventions recorded: AMXI-5001:Dose Escalation Phase I and AMXI-5001:Dose Expansion Phase II.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04503265
- Phase: 1/2
- Setting: A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies
- Sponsor: AtlasMedx, Incorporated
- Enrolled: 122

## Sources

- ClinicalTrials.gov NCT04503265: https://clinicaltrials.gov/study/NCT04503265

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct04503265.json